-
Alivus Life Sciences Analyst Review 2027: Profit Jumps 51% as Stock Runs Past Broker Target
- November 18, 2026
- Posted by: Chaitanya Auti
- Category: Market
No Comments
Alivus Life Sciences, formerly Glenmark Life Sciences, grew Q2 FY27 profit about 51% to ₹196.7 crore on a 41.8% EBITDA margin, and the stock now trades above ICICI Securities’ ₹1,330 target. We review results, segments, guidance and risks.